A new therapeutic strategy in breast cancer: Metronomic chemotherapy;Una nueva estrategia terapéutica en el cáncer de mama: Quimioterapia metronómica

Anales de Medicina Interna

Volumn 24, Issue 6, 2007, Pages 261-262

  Khosravi Shahi, P ^a   Perez Manga G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; LETROZOLE; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOSTATIC AGENT;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; EDITORIAL; HORMONAL THERAPY; IMMUNOTHERAPY; METASTASIS; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; PAGET NIPPLE DISEASE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS AS TOPIC; CYTOSTATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS;

EID: 38449088579     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Jemal A, Tiwani RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Ford D, Easton DF, Stratton M.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 1998; 62: 676-81.
3. Orlando L, Cardillo A, Rocca A, et al. Prolonged benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drug 2006; 17: 961-7.
4. Colleoni M, Rocca A, Sandri MT, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor leves. Ann Oncol 2002; 13: 73-80.
5. Khosravi P. Angiogénesis y neoplasias. An Med Interna (Madrid) 2006; 23: 355-6.
6. Munoz R, Man S, Shaked Y, et al. Higly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006; 66: 3386-91.
7. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozol and letrozol plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006; 24: 3623-8.
8. Burstein HJ. The distinctive nature of HER2 of breast cancers. N Engl J Med 353; 16: 1652-4.
9. Khosravi P, Pérez-Manga G. La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama. An Med Interna (Madrid) 2006; 23: 103-4.
10. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patioents with Her-2 positive metastatic breast cancer. BMC Cancer 2006; 6: 225-33.